Neuroendocrine tumors of midgut and hindgut origin: Tumor-node-metastasis classification determines clinical outcome

Cancer

Volumn 117, Issue 15, 2011, Pages 3332-3341

  Jann, Henning ^a   Roll, Stephanie ^a   Couvelard, Anne ^b   Hentic, Olivia ^b   Pavel, Marianne ^a   Müller Nordhorn, Jacqueline ^a   Koch, Martin ^a   Röcken, Christoph ^a,c   Rindi, Guido ^d   Ruszniewski, Philippe ^b   Wiedenmann, Bertram ^a   Pape, Ulrich Frank ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b BEAUJON HOSPITAL   (France)

^c UNIVERSITY OF KIEL   (Germany)

^d UNIVERSITY OF PARMA   (Italy)

Author keywords

carcinoid tumor; grading; neuroendocrine tumor; prognostic stratification; survival analysis; TNM staging

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER GRADING; CANCER STAGING; CARCINOID SYNDROME; CHILD; FEMALE; HINDGUT NEUROENDOCRINE TUMOR; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDGUT NEUROENDOCRINE TUMOR; NEUROENDOCRINE TUMOR; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; SCHOOL CHILD; WORLD HEALTH ORGANIZATION;

EID: 79959930250     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25855     Document Type: Article

References (40)

1. Modlin IM, Oberg K, Chung DC, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008; 9: 61-72.
2. Kloppel G, Perren A, Heitz PU,. The gastroenteropancreatic neuroendocrine cell system and its tumors. The WHO classification. Ann N Y Acad Sci. 2004; 1014: 13-27. (Pubitemid 38594787)
3. Wang Y, Giel-Moloney M, Rindi G, Leiter AB,. Enteroendocrine precursors differentiate independently of Wnt and form serotonin expressing adenomas in response to active beta-catenin. Proc Natl Acad Sci U S A. 2007; 104: 11328-11333. (Pubitemid 47175140)
4. Rindi G, Kloppel G, Ahlmann H, et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2006; 449: 395-401. (Pubitemid 44451313)
5. Modlin IM, Lye KD, Kidd M,. A 5-decade analysis of 13,715 carcinoid tumours. Cancer. 2003; 97: 934-959. (Pubitemid 36173145)
6. Pape UF, Berndt U, Muller-Nordhorn J, et al. Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer. 2008; 15: 1083-1097.
7. Caplin ME, Buscombe JR, Hilson AJ, Jones AL, Watkinson AF, Burroughs AK,. Carcinoid tumour. Lancet. 1998; 352: 799-805. (Pubitemid 128717532)
8. Zuetenhorst JM, Bonfrer JM, Korse CM, Bakker R, van Tinteren H, Taal BG,. Carcinoid heart disease: the role of urinary 5-hydroxyindoleacetic acid excretion and plasma levels of atrial natriuretic peptide, transforming growth factor-beta and fibroblast growth factor. Cancer. 2003; 97: 1609-1615. (Pubitemid 36350703)
9. Bhattacharyya S, Davar J, Dreyfus G, Caplin ME,. Carcinoid heart disease. Circulation. 2007; 116: 2860-2865. (Pubitemid 350301147)
10. Druce M, Rockall A, Grossman AB,. Fibrosis and carcinoid syndrome: from causation to future therapy. Nat Rev Endocrinol. 2009; 5: 276-283.
11. Modlin IM, Kidd M, Latich I, Zikusoka MN, Shapiro MD,. Current status of gastrointestinal carcinoids. Gastroenterology. 2005; 128: 1717-1751. (Pubitemid 40692562)
12. Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008; 26: 3063-3072.
13. Pape UF, Bohmig M, Berndt U, Tiling N, Wiedenmann B, Plockinger U,. Survival and clinical outcome of patients with neuroendocrine tumors of the gastroenteropancreatic tract in a German referral center. Ann N Y Acad Sci. 2004; 1014: 222-233. (Pubitemid 38594810)
14. Solcia E, Kloppel G, Sobin LH,. Histological typing of endocrine tumours. In: WHO: International Histological Classification of Tumours. Berlin, Germany: Springer; 2000.
15. Garcia-Yuste M, Matilla JM, Alvarez-Gago T, et al. Prognostic factors in neuroendocrine lung tumors: a Spanish Multicenter Study. Spanish Multicenter Study of Neuroendocrine Tumors of the Lung of the Spanish Society of Pneumonology and Thoracic Surgery (EMETNE-SEPAR). Ann Thorac Surg. 2000; 70: 258-263.
16. Asamura H, Kameya T, Matsuno Y, et al. Neuroendocrine neoplasms of the lung: a prognostic spectrum. J Clin Oncol. 2006; 24: 70-76. (Pubitemid 46630496)
17. Capella C, Heitz PU, Hofler H, Solcia E, Kloppel G,. Revised classification of neuroendocrine tumors of the lung, pancreas and gut. Vichows Arch. 1995; 452: 547-560.
18. Panzuto F, Nasoni S, Falconi M, et al. Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocr Relat Cancer. 2005; 12: 1083-1092. (Pubitemid 41815799)
19. Bahra M, Jacob D, Pascher A, et al. Surgical strategies and predictors of outcome for malignant neuroendocrine tumors of the pancreas. J Gastroenterol Hepatol. 2007; 22: 930-935. (Pubitemid 46911030)
20. Tomassetti P, Campana D, Piscitelli L, et al. Endocrine tumors of the ileum: factors correlated with survival. Neuroendocrinology. 2006; 83: 380-386. (Pubitemid 44729795)
21. Ahmed A, Turner G, King B, et al. Midgut neuroendocrine tumours with liver metastases. Results of the UKINETS study. Endocr Relat Cancer. 2009; 16: 885-894.
22. Pape UF, Jann H, Muller-Nordhorn J, et al. Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer. 2008; 113: 256-265.
23. Fischer L, Kleeff J, Esposito I, et al. Clinical outcome and long-term survival in 118 consecutive patients with neuroendocrine tumours of the pancreas. Br J Surg. 2008; 95: 627-635.
24. Ekeblad S, Skogseid B, Dunder K, Oberg K, Eriksson B,. Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution. Clin Cancer Res. 2008; 14: 7798-7803.
25. La Rosa S, Klersy C, Uccella S, et al. Improved histologic and clinicopathologic criteria for prognostic evaluation of pancreatic endocrine tumors. Hum Pathol. 2009; 401: 30-40.
26. Rindi G, Kloppel G, Couvelard A, et al. TNM staging of midgut and hindgut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2007; 451: 757-762. (Pubitemid 47497934)
27. Hochwald SN, Zee S, Conlon KC, et al. Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol. 2002; 20: 2633-2642. (Pubitemid 34575635)
28. Pelosi G, Bresaola E, Bogina G, et al. Endocrine tumors of the pancreas: Ki-67 immunoreactivity on paraffin sections is an independent predictor for malignancy: a comparative study with proliferating-cell nuclear antigen and progesterone receptor protein immunostaining, mitotic index, and other clinicopathologic variables. Hum Pathol. 1996; 27: 1124-1134. (Pubitemid 26374929)
29. Jorda M, Ghorab Z, Fernandez G, Nassiri M, Hanly A, Nadji M,. Low nuclear proliferative activity is associated with nonmetatatic islet cell tumors. Arch Pathol Lab Med. 2003; 127: 196-199. (Pubitemid 36231766)
30. Garcia-Carbonero R, Capdevila J, Crespo-Herrero G, et al. Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE). Ann Oncol. 2010; 21: 1794-1803.
31. Williams ED, Sandler M,. The classification of carcinoid tumours. Lancet. 1963; 1: 238-239.
32. Bettini R, Boninsegna L, Mantovani W, et al. Prognostic factors at diagnosis and value of WHO classification in a mono-institutional series of 180 non-functioning pancreatic endocrine tumours. Ann Oncol. 2008; 19: 903-908. (Pubitemid 351627305)
33. Bajetta E, Catena L, Procopio G, et al. Is the new WHO classification of neuroendocrine tumours useful for selecting an appropriate treatment? Ann Oncol. 2005; 16: 1374-1380. (Pubitemid 41158484)
34. Klimstra DS, Modlin IR, Adsay NV, et al. Pathology reporting of neuroendocrine tumors: Application of the Delphic consensus process to the development of a minimum pathology data set. Am J Surg Pathol. 2010; 34: 300-313.
35. Kloppel G, Rindi G, Perren A, Komminoth P, Klimstra DS,. The ENETS and AJCC/UICC TNM classifications of the neuroendocrine tumors of the gastrointestinal tract and the pancreas: a statement. Virchows Arch. 2010; 456: 595-597.
36. Boudreaux JP, Klimstra DS, Hassan MM, et al. The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the jejunum, ileum, appendix, and cecum. Pancreas. 2010; 39: 753-766.
37. Quaedvlieg PF, Visser O, Lamers CB, Janssen-Heijen ML, Taal BG,. Epidemiology and survival in patients with carcinoid disease in The Netherlands. An epidemiological study with 2391 patients. Ann Oncol. 2001; 12: 1295-1300. (Pubitemid 32994760)
38. Kirshbom PM, Kherani AR, Onaitis MW, Feldman JM, Tyler DS,. Carcinoids of unknown origin: comparative analysis with foregut, midgut, and hindgut carcinoids. Surgery. 1998; 124: 1063-1070. (Pubitemid 28555194)
39. Onaitis MW, Kirshbom PM, Hayward TZ, et al. Gastrointestinal carcinoids: characterization by site of origin and hormone production. Ann Surg. 2000; 232: 549-556.
40. Vilar E, Salazar R, Perez-Garcia J, Cortes J, Oberg K, Tabernero J,. Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors. Endocr Relat Cancer. 2007; 14: 221-232. (Pubitemid 47242624)